文献速递神经肿瘤

基于芯片数字PCR检测脑脊液ctDNA实现弥漫性胶质瘤分子诊断

Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
PubMed 文献 · J Neurooncol · 2021-01-08

本研究纳入34例弥漫性胶质瘤患者,采集开颅术中脑脊液及11例术前腰椎穿刺脑脊液,用芯片数字PCR检测IDH1 R132H、TERT启动子(C228T/C250T)和H3F3A K27M突变,并与肿瘤DNA对比。28例肿瘤DNA可检出诊断突变者中,20例(71%)经颅内脑脊液实现精准分子诊断;WHO分级(p=0.0034)、影像强化(p=0.0006)和Mib1指数(p=0.01)为预测因素。

要点

  • 脑脊液ctDNA芯片数字PCR可无创分子诊断弥漫性胶质瘤,高级别胶质瘤敏感性更高
  • WHO分级、影像强化和Mib1指数与脑脊液分子诊断成功显著相关
  • WHO III或IV级且肿瘤携带突变者中,腰穿脑脊液精准诊断率达6/7(87%)

核心结论

  • 基于芯片数字PCR检测脑脊液ctDNA可高灵敏度和特异度地无创分子诊断弥漫性胶质瘤,尤其适用于高级别胶质瘤。

研究设计与样本

  • 前瞻性收集34例弥漫性胶质瘤患者开颅术中脑脊液,其中11例另采集术前腰椎穿刺脑脊液,提取ctDNA行芯片数字PCR检测并与肿瘤DNA对比。

主要发现

  • 34例肿瘤DNA中28例检出诊断突变,其中20例(71%)经颅内脑脊液获得精准分子诊断。
  • 单因素分析显示WHO分级(p=0.0034)、影像强化(p=0.0006)和Mib1指数(p=0.01)是脑脊液精准分子诊断的显著预测因素。
  • 7例肿瘤携带突变的WHO III或IV级患者中,6例(87%)经腰穿脑脊液获得精准诊断。

关键数值与推荐

  • 检测靶点为IDH1 R132H、TERT启动子C228T和C250T及H3F3A K27M突变,采用QuantStudio® 3D Digital PCR System。
  • 颅内脑脊液分子诊断成功率为20/28(71%),腰穿脑脊液在高级别胶质瘤中为6/7(87%)。

临床怎么用

  • 对于高级别弥漫性胶质瘤,可考虑用脑脊液ctDNA芯片数字PCR辅助无创分子分型,减少对肿瘤组织依赖。

局限性

  • 样本量较小(34例),腰穿脑脊液数据仅来自11例,尚需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Conventional genetic analyzers require surgically obtained tumor tissues to confirm the molecular diagnosis of diffuse glioma. Recent technical breakthroughs have enabled increased utilization of cell-free tumor DNA (ctDNA) in body fluids as a reliable resource for molecular diagnosis in various cancers. Here, we tested the application of a chip-based digital PCR system for the less invasive diagnosis (i.e., liquid biopsy) of diffuse glioma using the cerebrospinal fluid (CSF). METHODS: CSF samples from 34 patients with diffuse glioma were collected from the surgical field during craniotomy. Preoperative lumbar CSF collection was also performed in 11 patients. Extracted ctDNA was used to analyze diagnostic point mutations in IDH1 R132H, TERT promoter (C228T and C250T), and H3F3A (K27M) on the QuantStudio® 3D Digital PCR System. These results were compared with their corresponding tumor DNA samples. RESULTS: We detected either of the diagnostic mutations in tumor DNA samples from 28 of 34 patients. Among them, we achieved precise molecular diagnoses using intracranial CSF in 20 (71%). Univariate analyses revealed that the World Health Organization (WHO) grade (p = 0.0034), radiographic enhancement (p = 0.0006), and Mib1 index (p = 0.01) were significant predictors of precise CSF-based molecular diagnosis. We precisely diagnosed WHO grade III or IV diffuse gliomas using lumbar CSF obtained from 6 (87%) of 7 patients with tumors harboring any mutation. CONCLUSION: We established a novel, non-invasive molecular diagnostic method using a chip-based digital PCR system targeting ctDNA derived from CSF with high sensitivity and specificity, especially for high-grade gliomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Fujioka Y, Hata N, Akagi Y, et al. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid. J Neurooncol. 2021. PMID: 33417137. doi:10.1007/s11060-020-03682-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。